Dr Dionysis Papadatos-Pastos

Medical oncologist in London

MD PhD MRCP(UK)

GMC: 6146326

6 Valoraciones de pacientes Valorar al doctor

Call

Book online

Telemedicine

Call

Book online

Telemedicine

Dr Dionysis Papadatos-Pastos areas of expertise:

Professional statement

Dr Dionysis Papadatos-Pastos is a consultant medical oncologist in London. He is the lead for lung cancer in the CRUK UCL Clinical Trials Centre and the joint lead for oncology in The Princess Alexandra Hospital.

He specialises in the treatment of lung cancer, mesothelioma, and thymoma. Throughout his career, he has gained extensive experience in cancer management using treatments such as immunotherapy, targeted therapies and chemotherapy.

He graduated in medicine at the University of Athens with distinction, which was followed by his PhD in Medical Oncology in 2012, with First Class honours. He trained in medical oncology at The Royal Marsden, St George’s University Hospitals and Guy’s and St Thomas’. He was awarded a diploma in medical oncology at the Institute of Cancer Research at the University of London.

Dr Papadatos-Pastos is an avid researcher and has been the principal investigator on multiple academic and commercial clinical trials. He has also presented at conferences, nationally and worldwide. His topics of research include the development of novel targeted therapies for the treatment of lung cancer, and assessing combinations of immunotherapy drugs with other anti-cancer compounds. Furthermore, he has been widely published in scientific medical journals and peer-reviewed papers.

Reviews

Treatments

Articles

Diplomas y publicaciones

Images

Videos

Vídeos de doctor

What are the most effective targeted th...

Doctor's articles

Read all articles by Dr Dionysis Papadatos-Pastos

Credentials

GMC: ‍6146326

Professional experience

• More than 20 years of experience
• Consultant Medical Oncologist, The London Clinic, Central London (present)
• Consultant Medical Oncologist, Leaders in Oncology Care (LOC), Central London (present)
• Consultant Medical Oncologist, University College London Hospitals NHS Foundation Trust (present)
• Consultant Medical Oncologist, Princess Alexandra Hospital NHS Foundation Trust, Harlow (present)
• Lead for lung cancer CRUK UCL Clinical Trials Centre
• joint lead for oncology, The Princess Alexandra Hospital

...

Sub-specialties

• Lung cancer
• Mesothelioma
• Thymoma
• Immunotherapy
• Targeted therapies
• Chemotherapy

...

Education

• PhD Medical Oncology University of Crete (2012)
• Degree in Medicine Athens University (2002)

Publications and conferences

• First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors,Clin Cancer Res . 2020 Sep 15;26(18):4777-4784
• HyPeR: A phase 1, dose escalation and expansion trial of guadecitabine (SGI-110), a second-generation hypomethylating agent in combination with pembrolizumab (MK3475) in patients with refractory solid tumors, AACR Annual Meeting 2020; April 27-28, 2020
• Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit, Eur J Cancer . 2017 Apr;75:56-62
• A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors, Clin Cancer Res . 2012 May 1;18(9):2687-94
• Combining targeted therapeutics in the era of precision medicine, Br J Cancer 2015;112:1-3
• Delayed onset immune related adverse effects (IRAEs) of pembrolizumab in non-small cell lung cancer, 2019, ESMO Annual Meeting, 1510P
• A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma, 2011 ASCO annual meeting
• A first-in-human phase I study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin’s lymphoma (NHL), 2010 ESMO annual meeting
• Should patients with malignant intracranial space occupying lesions (M-ICSOLs) be excluded from phase I trials? The Royal Marsden Hospital Drug Development Unit experience. 2010 ASCO annual meeting 2010, received the ASCO foundation Merit Award.
• A Multicentric, Retrospective, Real-world Study on Immune-related Adverse Events in Patients with Advanced Non-small Cell Lung Cancers Treated with Pembrolizumab Monotherapy. Clin Oncol (R Coll Radiol). 2024 Jan 16:S0936-6555(24)00025-6. doi: 10.1016/j.clon.2024.01.009. Online ahead of print.
• The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature. 2023 Apr;616(7957):525-533. doi: 10.1038/s41586-023-05783-5. Epub 2023 Apr 12. PMID: 37046096
• The evolution of non-small cell lung cancer metastases in TRACERx. Nature. 2023 Apr;616(7957):534-542. doi: 10.1038/s41586-023-05729-x. Epub 2023 Apr 12. PMID: 37046095
• Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors. J Immunother Cancer. 2022 Jun;10(6):e004495. doi: 10.1136/jitc-2022-004495. PMID: 35717027 Free PMC article. Clinical Trial.

...

Prizes and awards

• ASCO (American Society of Clinical Oncology) Merit Award (2010)

Professional membership

• Royal College of Physicians
• Medical Defence Union
• General Medical Council

...

Languages spoken

English
Greek